Guggenheim Maintains Buy on Merck & Co, Raises Price Target to $171
Benzinga Newsdesk 23 hours ago
Analyst RatingsNewsPrice TargetHot
Guggenheim analyst Vamil Divan maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $170 to $171.
Guggenheim analyst Vamil Divan maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $170 to $171.